Eli Lilly and Company’s (LLY) “Outperform” Rating Reiterated at Royal Bank Of Canada

Eli Lilly and Company (NYSE:LLY – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $1,600.00 target price on the stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 12.00% from the stock’s current price.

Several other research firms have also issued reports on LLY. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Friday. China Merchants Securities downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, November 12th. Scotiabank boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research report on Friday, October 30th. Barclays increased their price objective on Eli Lilly and Company from $1,400.00 to $1,550.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.

Read Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,428.61 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $1.34 trillion, a PE ratio of 45.90, a P/E/G ratio of 1.71 and a beta of 0.40. The firm has a fifty day simple moving average of $1,247.93 and a two-hundred day simple moving average of $1,112.33. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the firm earned $7.02 earnings per share. Research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several large investors have recently bought and sold shares of LLY. Torren Management LLC raised its holdings in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares in the last quarter. Foresight Capital Management Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $49,000. AlphaCentric Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $42,000. Sumitomo Mitsui Financial Group Inc. boosted its position in shares of Eli Lilly and Company by 5,100.0% in the 3rd quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company’s stock worth $60,000 after purchasing an additional 51 shares in the last quarter. Finally, Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $64,000. 82.53% of the stock is owned by institutional investors.

Recent Eli Lilly and Company Headlines

Here are a few of the latest headlines about LLY:

  • Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—to its pipeline. The deal broadens Lilly’s portfolio beyond obesity and diabetes. Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
  • Positive Sentiment: Barclays raised its price target to $1,550 from $1,400 and maintained an Overweight rating, signaling a more bullish view of Lilly’s prospects.
  • Neutral Sentiment: Lilly also signed a cancer-research deal with Stipple Bio valued at up to $5.9 billion. The collaboration adds another potential source of pipeline growth, but the headline value is a maximum and the available report provides limited detail on payment timing or milestones. Lilly signs cancer research deal with Stipple Bio

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.